Back غلاكسو سميث كلاين Arabic جلاكسو سميث كلاين ARZ قلاکسواسمیتکلاین AZB গ্লাক্সোস্মিথক্লাইন Bengali/Bangla GlaxoSmithKline Catalan GlaxoSmithKline Czech GlaxoSmithKline Danish GSK (Pharmaunternehmen) German GlaxoSmithKline Greek GlaxoSmithKline EO
 Logo since 9 June 2022 | |
.jpg) Head office in Brentford, London with the former GlaxoSmithKline logo, taken on 30 July 2007 | |
| Formerly | GlaxoSmithKline (2000–2022) |
|---|---|
| Company type | Public limited company |
| Industry | |
| Predecessors |
|
| Founded | 27 December 2000 |
| Headquarters | London, England, UK |
Area served | Worldwide |
Key people |
|
| Products | |
| Revenue |  £30.328 billion (2023)[1] |
| £6.745 billion (2023)[1] | |
| £5.308 billion (2023)[1] | |
| Total assets |  £59.005 billion (2023)[1] |
| Total equity | £12.795 billion (2023)[1] |
Number of employees | 70,000 (2024)[2] |
| Subsidiaries | |
| Website | www |
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London.[3][4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham,[n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
GSK is the tenth largest pharmaceutical company and No. 294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck Sharp & Dohme.[5]
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of February 2024, it had a market capitalisation of £69 billion, the eighth largest on the London Stock Exchange.[6]
The company developed the first malaria vaccine, RTS,S, which it said in 2014, it would make available for five per cent above cost.[7] Legacy products developed at GSK include several listed in the World Health Organization's List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine and zidovudine.[8]
In 2012, under prosecution by the United States Department of Justice (DoJ) based on combined investigations of the Department of Health and Human Services (HHS-OIG), FDA and FBI, primarily concerning sales and marketing of the drugs Avandia, Paxil and Wellbutrin, GSK pleaded guilty to promotion of drugs for unapproved uses, failure to report safety data and kickbacks to physicians in the United States and agreed to pay a US$3 billion (£1.9bn) settlement. It was the largest health-care fraud case to date in the US and the largest settlement in the pharmaceutical industry.[9]
- ^ a b c d e "Preliminary Results 2023" (PDF). GSK. Retrieved 11 February 2024.
- ^ "At a glance". GSK. Retrieved 11 February 2024.
- ^ "Headquarters | GSK US". us.gsk.com. Archived from the original on 22 May 2022. Retrieved 17 June 2022.
- ^ "GlaxoSmithKline on the Forbes Top Multinational Performers List". Forbes. Archived from the original on 26 January 2021. Retrieved 11 December 2017.
- ^ "Global 500". Fortune. Archived from the original on 5 April 2023. Retrieved 10 August 2022.
- ^ "FTSE All-Share Index Ranking". stockchallenge.co.uk. Archived from the original on 26 March 2023. Retrieved 10 August 2022.
- ^ Plumridge H (24 July 2014). "Glaxo Files Its Entry in Race for a Malaria Vaccine". The Wall Street Journal. Archived from the original on 20 October 2020. Retrieved 13 March 2017.
Lorenzetti L (24 July 2014). "GlaxoSmithKline seeks approval on first-ever malaria vaccine". Fortune. Archived from the original on 25 April 2016. Retrieved 16 August 2014.
- ^ Cite error: The named reference
WHO21stwas invoked but never defined (see the help page). - ^ Cite error: The named reference
USDOJJuly2012was invoked but never defined (see the help page).
Cite error: There are <ref group=n> tags on this page, but the references will not show without a {{reflist|group=n}} template (see the help page).